Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ: YMAB )

6.240 +0.070 (+1.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 903,689
Open 6.310
Bid (Size) 6.230 (33)
Ask (Size) 6.240 (2)
Prev. Close 6.170
Today's Range 6.170 - 6.650
52wk Range 5.600 - 20.90
Shares Outstanding 44,789,076
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
Via Benzinga

Performance

YTD
-21.71%
-21.71%
1 Month
+0.97%
+0.97%
3 Month
-41.79%
-41.79%
6 Month
-50.04%
-50.04%
1 Year
-61.69%
-61.69%

More News

Read More
Y-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
Via Benzinga
Examining the Future: Y-mAbs Therapeutics's Earnings Outlook
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Navigating 8 Analyst Ratings For Y-mAbs Therapeutics
Via Benzinga
Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
Via Benzinga
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
Via The Motley Fool
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
From Pomerantz LLP
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Via Benzinga
Earnings Outlook For Y-mAbs Therapeutics
Via Benzinga
MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
Via Investor's Business Daily
Micro Marvel - Y-Mabs Therapeutics
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.